Beyfortus (nirsevimab) approved in EU
4 November 2022 07:00 GMT Beyfortus approved in the EU for the prevention of RSV lower respiratory tract disease in infants First and only single-dose RSV preventative option approved for broad newborn and infant population European Commission grants first approval worldwide following positive CHMP opinion in September AstraZeneca and Sanofi's Beyfortus (nirsevimab) has been approved in the European Union (EU) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants during their first RSV season.[1] Beyfortus is